Clinical findings and prognosis of Danon’s Disease. An analysis from the Spanish multicenter Danon Registry.

Introducción y objetivos: La enfermedad de Danon (ED) es una enfermedad poco frecuente producida por mutaciones en el gen LAMP2. Se considera una enfermedad multisistémica caracterizada por: miocardiopatía hipertrófica con preexcitación y gran hipertrofia, discapacidad intelectual, miopatía, presentación infantil y peor pronóstico en varones. Existen pocas series que permitan conocer las características clínicas y el pronóstico de la ED en detalle. Métodos Estudio retrospectivo basado en el análisis de los registros clínicos de los pacientes con ED seguidos en 10 hospitales españoles. Resultados Se incluyeron 28 pacientes (3220años, 79% mujeres). Los varones demostraron una elevada prevalencia de manifestaciones extracardiacas: miopatía (80%), trastornos del aprendizaje (83%) y alteraciones visuales (60%), siendo hallazgos infrecuentes en las mujeres (5%, 0% y 24%, respectivamente). Aunque la miocardiopatía hipertrófica era la cardiopatía más habitual (67%), el grosor máximo ventricular fue 157 mm y 12 pacientes (10 mujeres) se presentaron con miocardiopatía dilatada. Sólo 11 pacientes (46%) (4 hombres y 7 mujeres) mostraron preexcitación y en 16 (67%) la enfermedad debutó por encima de los 20 años. Tras una mediana de seguimiento de 4 años (P25-752-9), 4 varones (67%) y 9 mujeres (41%) fallecieron o requirieron un trasplante. Tanto la afectación cardiaca como los eventos adversos ocurrieron más tardíamente en mujeres (37±9 vs 23±16 y 38±21 vs 20±11 años, respectivamente). Conclusiones. Las características clínicas de la ED difieren substancialmente de lo tradicionalmente considerado. La edad de presentación de la ED es más tardía, no se expresa como una patología multisistémica en mujeres y la preexcitación es poco frecuente. Aunque las mujeres presentan mal pronóstico, los eventos adversos ocurren a una edad más avanzada.Background Danon's disease (DD) is a rare disease caused by mutations in the LAMP2 gene. It is considered a multisystemic disease characterized by: hypertrophic cardiomyopathy with preexcitation and ventricular hypertrophy, intellectual disability, myopathy, childhood presentation and worse prognosis in men. Available data regarding clinical characteristics and the prognosis of the DD are scarce. Methods Retrospective study based on the analysis of the clinical records of patients with ED from 10 Spanish hospitals. Results Twenty-eight patients were included (32±20 years, 79% women). Males showed a high prevalence of extracardiac manifestations: myopathy (80%), learning disorders (837%) and visual alterations (60%), which were uncommon findings in women (5%, 0% and 24%, respectively). Although hypertrophic cardiomyopathy was the most common form of heart disease (67%), maximum wall thickness was 15±7 mm and 12 patients (10 women) presented as dilated cardiomyopathy. Only 11 patients (467%) (4 men and 7 women) showed preexcitation and in 16 (67%) the disease started above 20 years-old. After a median follow-up of 4 years (P25-75: 2-9), 4 men (67%) and 9 women (41%) died or required a heart transplant. Both cardiac involvement and adverse events occurred later in women (37 ± 9 vs 23 ± 16 and 38± 21 vs 20 ± 11 years, respectively). Conclusions Clinical characteristics of DD differ substantially from what has been traditionally considered. ED usually presents at an increased age, is not a multisystemic disease in women and preexcitation is rare. Even though, women show also a poor prognosis, adverse events occur at a later age.pre-print518 K

Predictores de riesgo en una cohorte española con cardiolaminopatías. Registro REDLAMINA

[Abstract] Introduction and objectives. According to sudden cardiac death guidelines, an implantable cardioverter-defibrillator (ICD) should be considered in patients with LMNA-related dilated cardiomyopathy (DCM) and ≥ 2 risk factors: male sex, left ventricular ejection fraction (LVEF) < 45%, nonsustained ventricular tachycardia (NSVT), and nonmissense genetic variants. In this study we aimed to describe the clinical characteristics of carriers of LMNA genetic variants among individuals from a Spanish cardiac-laminopathies cohort (REDLAMINA registry) and to assess previously reported risk criteria. Methods. The relationship between risk factors and cardiovascular events was evaluated in a cohort of 140 carriers (age ≥ 16 years) of pathogenic LMNA variants (54 probands, 86 relatives). We considered: a) major arrhythmic events (MAE) if there was appropriate ICD discharge or sudden cardiac death; b) heart failure death if there was heart transplant or death due to heart failure. Results. We identified 11 novel and 21 previously reported LMNA-related DCM variants. LVEF < 45% (P = .001) and NSVT (P < .001) were related to MAE, but not sex or type of genetic variant. The only factor independently related to heart failure death was LVEF < 45% (P < .001). Conclusions. In the REDLAMINA registry cohort, the only predictors independently associated with MAE were NSVT and LVEF < 45%. Therefore, female carriers of missense variants with either NSVT or LVEF < 45% should not be considered a low-risk group. It is important to individualize risk stratification in carriers of LMNA missense variants, because not all have the same prognosis.[Resumen] Introducción y objetivos. Según las guías de muerte súbita, se debe considerar un desfibrilador automático implantable (DAI) para los pacientes con miocardiopatía dilatada debida a variantes en el gen de la lamina (LMNA) con al menos 2 factores: varones, fracción de eyección del ventrículo izquierdo (FEVI) < 45%, taquicardia ventricular no sostenida (TVNS) y variantes no missense. Nuestro objetivo es describir las características clínicas de una cohorte española de pacientes con cardiolaminopatías (registro REDLAMINA) y evaluar los criterios de riesgo vigentes. Métodos. Se evaluó la relación entre factores de riesgo y eventos cardiovasculares en una cohorte de 140 portadores de variantes en LMNA (54 probandos, 86 familiares, edad ≥ 16 años). Se consideró: a) evento arrítmico mayor (EAM) si hubo descarga apropiada del DAI o muerte súbita, y b) muerte por insuficiencia cardiaca, incluidos los trasplantes. Resultados. Se identificaron 11 variantes nuevas y 21 previamente publicadas. La FEVI < 45% (p = 0,001) y la TVNS (p < 0,001) se relacionaron con los EAM, pero no el sexo o el tipo de variante (missense frente a no missense). La FEVI < 45% (p < 0,001) fue el único factor relacionado con la muerte por insuficiencia cardiaca. Conclusiones. En el registro REDLAMINA, los únicos 2 predictores asociados con EAM fueron la TVNS y la FEVI < 45%. No se debería considerar grupo de bajo riesgo a las portadoras de variantes missense con TVNS o FEVI < 45%. Es importante individualizar la estratificación del riesgo de los portadores de variantes missense en LMNA, porque no todas tienen el mismo pronóstico.This study received a grant from the Proyecto de investigación de la Sección de Insuficiencia Cardiaca 2017 from the Spanish Society of Cardiology and grants from the Instituto de Salud Carlos III (ISCIII) [PI14/0967, PI15/01551, AC16/0014] and ERA-CVD Joint Transnational Call 2016 (Genprovic). Grants from the ISCIII and the Ministerio de Economía y Competitividad de España (Spanish Department of Economy and Competitiveness) are supported by the Plan Estatal de I+D+i 2013-2016: Fondo Europeo de Desarrollo Regional (FEDER) “Una forma de hacer Europa”

Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives

BACKGROUND Disease penetrance in genotype -positive (G+) relatives of families with dilated cardiomyopathy (DCM) and the characteristics associated with DCM onset in these individuals are unknown. OBJECTIVES This study sought to determine the penetrance of new DCM diagnosis in G+ relatives and to identify factors associated with DCM development. METHODS The authors evaluated 779 G+ patients (age 35.8 +/- 17.3 years; 459 [59%] females; 367 [47%] with variants in TTN ) without DCM followed at 25 Spanish centers. RESULTS After a median follow-up of 37.1 months (Q1 -Q3: 16.3-63.8 months), 85 individuals (10.9%) developed DCM (incidence rate of 2.9 per 100 person -years; 95% CI: 2.3-3.5 per 100 person -years). DCM penetrance and age at DCM onset was different according to underlying gene group (log -rank P = 0.015 and P <0.01, respectively). In a multivariable model excluding CMR parameters, independent predictors of DCM development were: older age (HR per 1 -year increase: 1.02; 95% CI: 1.0-1.04), an abnormal electrocardiogram (HR: 2.13; 95% CI: 1.38-3.29); presence of variants in motor sarcomeric genes (HR: 1.92; 95% CI: 1.05-3.50); lower left ventricular ejection fraction (HR per 1% increase: 0.86; 95% CI: 0.82-0.90) and larger left ventricular end -diastolic diameter (HR per 1 -mm increase: 1.10; 95% CI: 1.06-1.13). Multivariable analysis in individuals with cardiac magnetic resonance and late gadolinium enhancement assessment (n = 360, 45%) identi fied late gadolinium enhancement as an additional independent predictor of DCM development (HR: 2.52; 95% CI: 1.43-4.45). CONCLUSIONS Following a first negative screening, approximately 11% of G+ relatives developed DCM during a median follow-up of 3 years. Older age, an abnormal electrocardiogram, lower left ventricular ejection fraction, increased left ventricular end -diastolic diameter, motor sarcomeric genetic variants, and late gadolinium enhancement are associated with a higher risk of developing DCM. (J Am Coll Cardiol 2024;83:1640 -1651) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Natural History of MYH7-Related Dilated Cardiomyopathy

BACKGROUND Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described. OBJECTIVES We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression. METHODS We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% female; 35.6 +/- 19.2 years) recruited from 29 international centers. RESULTS At initial evaluation, 106 (72.1%) patients had DCM (left ventricular ejection fraction: 34.5% +/- 11.7%). Median follow-up was 4.5 years (IQR: 1.7-8.0 years), and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years of age. Thirty-six percent of patients with DCM met imaging criteria for LV noncompaction. During follow-up, 28% showed left ventricular reverse remodeling. Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths caused by end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF of <= 35%, respectively). ESHF and major ventricular arrhythmia were significantly lower compared with LMNA-related DCM and similar to DCM caused by TTN truncating variants. CONCLUSIONS MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low left ventricular reverse remodeling, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare. (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation

Un estado funcional deteriorado se acompaña de un incremento en el índice de Tei. Estudio poblacional

El índice de Tei se ha descrito como más representativo de la disfunción cardiaca global que las medidas sistólicas o diastólicas. La New York Heart Association proporciona un método aceptado de clasificación funcional que presenta buena correlación con la función ventricular. En un estudio multicéntrico poblacional se han calculado los valores de Tei en diferentes clases funcionales de la NYHA

Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology

The research support source was from the National Institute of Health Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III, FIS 01/0943 Project, Spain.N-terminal pro-brain natriuretic peptide (NT-proBNP) may be useful in the diagnosis of heart failure and ventricular dysfunction. Obesity is an independent cardiovascular risk factor. The purpose of this study was to measure NT-proBNP plasma levels in obese and non-obese subjects with heart failure and to compare levels in subjects with ischaemic and dilated aetiology. In this study, obese subjects had 63% lower NT-proBNP plasma levels than non-obese subjects (p<0.01). In multivariate analysis, BMI was inversely associated with NT-proBNP plasma levels (p<0.05) and a 17% decrease in natriuretic peptide levels was attributed to obesity (p<0.036). When we analyzed data according to the aetiology of heart failure, we found that both groups (ischaemic and dilated) had a 65% decrease in NT-proBNP plasma levels in obese subjects compared to non-obese subjects.Instituto de Salud Carlos II

Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failure

Aims N-terminal pro-brain natriuretic peptide (NT-proBNP) is useful in the diagnosis of heart failure (HF). LV two-dimensional cavity area from end-diastole (LVEDA) and end-systole (LVESA), and LV fractional area change (LVFAC) reflect changes in LV morphology and function without using geometric assumptions. In a multicenter study, we correlated LVEDA, LVESA and LVFAC with NT-proBNP, comparing patients with dilated and ischemic cardiomyopathy. Methods and results We studied 106 HF patients. In the dilated group, NT-proBNP correlated with LVEDAI ( r =0.6), LVESAI ( r =0.7) and LVFAC ( r =−0.6), all significant at p <0.001. In patients with ischemic cardiomyopathy we found LVESAI ( r =0.3, p <0.05) and LVFAC ( r =−0.4, p <0.01). After adjustment for age and BMI, LVFAC and LVESAI were associated in a multiple linear regression analysis with peptide levels (adjusted r2 =0.5, p <0.001). Conclusions In this study we found a good correlation of NT-proBNP with LV cavity areas and LVFAC. Multiple regression analysis showed that when adjusted for age and BMI, LVFAC and LVESAI are independent predictors of NT-proBNP levels in both dilated and ischemic etiologies. Patients with dilated cardiomyopathy showed better results than those with ischemic cardiomyopathy. We think LV areas are a useful and reproducible parameter, do not need geometric assumptions and reflect NT-proBNP plasma levels

NT-proBNP y desplazamiento del plano auriculoventricular: relación e implicaciones diagnósticas

Introducción y objetivos. El N-terminal propéptido natriurético cerebral (NT-proBNP) es útil en el diagnóstico de la insuficiencia cardíaca y la disfunción ventricular. El desplazamiento del plano auriculoventricular (DPAV) es un índice consolidado de la función ventricular. Nuestro objetivo es relacionar en un estudio multicéntrico poblacional los valores plasmáticos del NT-proBNP y los valores del DPAV. Pacientes y método. Estudiamos a 215 sujetos (edad, 66 ± 9 años; un 57,7%, mujeres) obtenidos de una muestra aleatoria de 432 personas de la Comunidad Valenciana que previamente declararon sufrir algún grado de disnea. Se realizó un estudio con eco-Doppler, se midió el DPAV y se determinó el valor plasmático de NT-proBNP. El estudio se completó en 194 pacientes. Resultados. Para toda la población, el valor de NT-proBNP fue de 88 pg/ml (rango, 0-2.586 pg/ml) y el valor del DPAV fue de 11,9 ± 1,6 mm. Las concentraciones del péptido natriurético muestran una correlación con los valores del DPAV (r = 0,44; p < 0,00001) y su valores más elevados se observan en los cuartiles del DPAV con menor desplazamiento (p < 0,05). Cuando agrupamos los valores del NT-proBNP en menor o mayor del percentil 50 del DPAV, obtuvimos un valor de p < 0,01. Si dividimos el DPAV en mayor o menor de 10 mm, los valores de NT-proBNP son más elevados en los sujetos con DPAV menor de 10 mm (p < 0,05). Conclusiones. Este estudio poblacional muestra valores más altos de NT-proBNP en sujetos con un desplazamiento menor del plano auriculoventricular, y pone de manifiesto su potencial diagnóstico en la práctica clínica